UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Dec 18, 2020
SOUTH PLAINFIELD, N.J. , Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of 12,500 shares of its common stock and 4,360 restricted stock units ("RSUs"), each representing
Additional Formats
Dec 09, 2020
SOUTH PLAINFIELD, N.J. , Dec. 9, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET . The Translarna Deep Dive will provide an overview of results from the clinical and real-world
Additional Formats
Dec 04, 2020
SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41,955 shares of its common stock and 20,735 restricted stock units ("RSUs"), each representing
Additional Formats
Dec 04, 2020
SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD).
Additional Formats
Nov 30, 2020
- Third trial initiated in 2020 from compounds identified from PTC's Bio-e platform - SOUTH PLAINFIELD, N.J. , Nov. 30, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in
Additional Formats
Nov 19, 2020
SOUTH PLAINFIELD, N.J. , Nov. 19, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET .
Additional Formats
Nov 18, 2020
SOUTH PLAINFIELD, N.J. , Nov. 18, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcoma
Additional Formats
Nov 17, 2020
- Initial clinical trial results expected in 1H 2021 - SOUTH PLAINFIELD, N.J. , Nov. 17, 2020 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing
Additional Formats
Nov 16, 2020
- AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy -   - Patient and caregiver quality of life study reveals real-life impact of nonsense mutation Duchenne muscular dystrophy and reinforces value of treatment - SOUTH
Additional Formats
Oct 29, 2020
- Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch -   - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase -   - Initiated registration-directed trial with vatiquinone (PTC743) for
Additional Formats